"We have chosen to expand the Form 10-QSB to provide the public and the investing community with more information about ACT, our technology, and our substantial intellectual property platform," said William Caldwell, Chief Executive Officer of ACT. "The report highlights our IP portfolio, which we believe represents one of the strongest portfolios in the field of stem cell and nuclear transfer technology. ACT will continue to focus on expanding our intellectual property portfolio which we anticipate will be useful in advancing our research, development and commercialization initiatives."

As noted in the Form 10-QSB, ACT currently owns or has licenses to over 30 patents and 280 patent applications pending worldwide in the field of stem cell and nuclear transfer technology. In particular, ACT has exclusively licensed what we believe to be the earliest and most detailed intellectual property on human therapeutic cloning from University of Massachusetts for applications of Somatic Cell Nuclear Transfer (SCNT). In recently published independent research, South Korean researchers announced success in therapeutic cloning using SCNT techniques.

"We believe that the use of SCNT for chronic disease applications, and our Reduced Complexity Program for acute disease applications, will provide the foundation for exciting advances in medicine over the next decade," said Michael West, Ph.D. President and Chief Scientific Officer of ACT. "Our strategy is to build on this technology and apply it as soon as is practical into clinical trials to demonstrate the validity of regenerative medicine in the marketplace."

To view the details of the report visit http://www.sec.gov/edgar.shtml

Source